Search

Abstract: Background: Although primary graft failure (PGF) after heart transplantation is a feared complication, most reports have come from Western countries. We analyzed the incidence in our hospital and tried to determine the predictive risk factors for PGF that require mechanical circulatory support or high dosage of inotropic agents after heart transplantation. We observed the long-term prognosis of patients successfully surviving PGF. Methods: For this retrospective review, 447 patients undergoing heart transplantation between January 1990 and January 2013 were enrolled in our study. We compared the clinical data between patients with PGF and without PGF. The risk factors associated with PGF were analyzed, and the long-term survival curve was analyzed using a Kaplan-Meier analysis. Results: The incidence of PGF in our study was 36.2% (162 patients) and the overall PGF-related mortality rate was 17% (30 day in-hospital mortality). Independent risk factors for PGF included preoperative recipient hypoalbuminemia, high central venous pressure, United Network for Organ Sharing (UNOS) status 1A, dependence on inotropic agents, ventilator, intra-aortic balloon pump (IABP), and extracorporeal membrane oxygenation (ECMO), and longer ischemic time. Patients with PGF had poorer long-term survival than patients without PGF; the 1-year survival rate was 40% versus 76% (P < .01). The rate of weaning from ECMO for PGF was 46% (12 of 26 patients) and they have similar 1-year survival rates as non-EGF patients. Conclusions: Several recipient and donor variables significantly influenced the PGF after heart transplantation. The mortality rate was higher in patients with PGF. However, patients who survived PGF have similar mid-term and long-term survival as patients without PGF. [Copyright &y& Elsevier]

Objective: Six-minute walk test (6MWT) is an important measure to assess the exercise capacity of cardiac patients. This study aimed to evaluate the correlations of 6MWT with findings of cardiopulmonary exercise testing (CPET), health-related quality of life (HRQoL), and obesity among heart transplantation recipients (HTR) at least 1 year after transplantation. Method: Clinically stable HTR were recruited for this study from the National Taiwan University Hospital, Taipei, Taiwan. The 6MWT was performed by a physical therapist following the American Thoracic Society standard. Each subject underwent a symptom-limited CPET to evaluate cardiorespiratory fitness and bioelectrical impendence analysis for determination of body composition. The HRQoL of study subjects was evaluated by the Medical Outcomes Trust 36-item health survey (SF-36). Results: The study subjects included 43 HTR (age: 47.8±11.1 years; 37 men, 6 women) at 4.8±3.2 years after transplantation. The 6MWT distance was 539±108 m (89.9±18.2% of the predicted value). The peak oxygen uptake was 19.3±4.7 mL/kg/min. The body composition analysis showed body fat percentage 25.2±7.9%, body mass index 26.5±4.8, and waist circumference 94.8±13.3 cm. The 6MWT distance was significantly positively correlated with peak oxygen uptake, peak heart rate, peak work rate, and peak systolic blood pressure during CPET, and significantly negatively correlated with body fat percentage, body mass index, and waist circumference. The 6MWT distance was also significantly positively correlated with SF-36 HRQoL parameters including general health perception and standardized physical component scale. The peak HR during CPET and standardized physical component scale was significantly correlated with 6MWT distance in multivariate analysis. Conclusions: Our findings indicate that 6MWT is a simple and useful measure to assess the exercise capacity of clinically stable HTR. The 6MWT distance is positively correlated with HRQoL and negatively correlated with obesity among HTR. The prognostic significance of 6MWT for HTR requires further investigation. [ABSTRACT FROM AUTHOR]

Abstract: Background: Cyclosporine (CsA) is widely used after heart transplantation. The purpose of this prospective randomized study was to evaluate the safety and efficacy of reduction of CsA blood level to one-half of the traditional blood concentration under a regimen of everolimus (EVL), CsA, and steroid. Materials and Methods: This prospective, 6 month, randomized, open-label study included adult (aged 18 to 65 years) recipients of a primary heart transplant with serum creatinine ≤2.8 mg/dL. Among 52 patients who underwent heart transplantation from December 2004 to March 2006 we excluded those who were hepatitis B or C carriers, who were recipients of organs from donors >60 years old, had cold ischemia time >6 hours, or had plasma renin activity ≥25%. All patients received CsA (C2 blood level 1000–1400 ng/mL), EVL (C0 target 3–8 ng/mL), and corticosteroids to day 60, before random entry into one of 2 groups: SE (C2 blood level from days 60–149 = 800–1200 ng/mL, and days 150–180 C2 = 600–1000 ng/mL), or RE group with CsA reduced by one-half after 3 months (days 90–149 C2 = 400–600 ng/mL, and from days 150–180 C2 = 300–500 ng/mL). Results: The 25 recipients eligible for this study included 13 patients in the SE and 12 in the RE group. There was no operative mortality in either group. No death or graft loss was noted within 6-months in either group. Mean serum creatinine at month 6 tended to be lower in the RE cohort (1.23 ± 0.44 mg/dL versus 1.55 ± 0.85 mg/dL; P = .093). Biopsy-proven acute rejection ≥ grade 3A was observed in only 1 patient (7.7%), who was in the SE group. There were no acute rejection episodes associated with hemodynamic compromise. The incidences of adverse events in each group were similar. Conclusions: Concentration-controlled EVL (C0 target 3–8 ng/mL) in combination with reduced CsA exposure of one-half the usual concentration achieved good efficacy and safety over 6 months. The renal function at 6 months among the RE group showed a trend toward improvement, suggesting a benefit of halving the target CsA blood level after heart transplantation. [Copyright &y& Elsevier]

Abstract: Heart transplantation (HTx) is indicated in children with end-stage heart failure or complex inoperable congenital defects. Because of the shortage of pediatric donor hearts, various bridge techniques have been used in pediatric patients to prolong patient survival until a suitable heart becomes available. We reviewed medical records of several pediatric patients in whom bridging with ventricular assist devices was used. All of the patients survived HTx, and are alive and well with no neurologic sequelae. They are NYHA functional class I. Thus, morbidity and mortality were acceptable in this high-risk group of pediatric patients with a ventricular assist device bridging to HTx. [Copyright &y& Elsevier]

Abstract: Cardiac transplantation is currently the only established surgical approach to the treatment of refractory heart failure. Heart transplantation because of amyloid cardiomyopathy continues to generate controversy because of donor shortage and concerns about disease recurrence in the allograft. We reviewed the medical records for all patients who underwent heart transplantation at our institution from 1987 to 2007, and found that 4 patients were diagnosed as having amyloid cardiomyopathy after pathologic examination of the excised hearts. No operative mortality was noted; however, all of the patients died of sepsis after transplantation. Because of the poor results, we do not recommended performing transplantation in patients with amyloidosis. Preoperative surveys and evaluation for amyloidosis must be emphasized in patients with hypertrophic cardiomyopathy. [Copyright &y& Elsevier]

Abstract: Ventricular assist devices (VAD) have benefited patients with end-stage heart failure as a bridge to heart transplantation (HTx). We present our experience of HTx in the presence of device-related infection (DRI) including driveline exit site with pocket infections. From May 1996 to April 2003, mechanical circulatory support with the HeartMate VAD was performed in eight patients, and with the Thoratec VAD in seven patients. Although 151 patients underwent HTx during that period, only 8 of the 15 patients had suitable donors and underwent orthotopic HTx. Six of the eight patients developed DRI. Their ages ranged from 18 to 59 years (mean = 36 ± 14 years). The duration of VAD support ranged from 8 to 287 days (mean = 125 ± 117 days). The general condition and cardiac function improved gradually under VAD support. At the time of HTx, all six male patients were suffering from DRI. The causative microorganisms were Acinetobacter baumannii (n = 3) methicillin-resistant Staphylococcus aureus (n = 2), and Enterococcus faecium (n = 1). All patients underwent successful HTx, and were discharged in good condition. It is concluded that under the coverage of appropriate antibiotics, HTx can be successfully performed for the patients for VAD support with DRI. It is important to prevent the spread of infection during HTx. Adequate debridement and drainage of the infected materials prevents postoperative wound infections. [Copyright &y& Elsevier]

Abstract: Introduction: Survival in patients with refractory heart failure greatly improves after heart transplantation (HTx). Objective: To evaluate the rate of unplanned readmission within the first year post-HTx and the causes of such readmission. Patients and Methods: From January 2005 to June 2008, the 112 patients who underwent HTx were regularly followed up at our hospital. A protocol biopsy was performed every week during the first month, then every 3 months during the first year. Any unplanned readmission was discussed in detail in a transplantation meeting. Data were collected from review of medical records. Results: The rate of unplanned readmission was 19.3% in 2005, 21.5% in 2006, 22.2% in 2007, and 20.3% in 2008. Infection was the primary cause leading to unplanned readmission in 2005 (51.5%), 2006 (42.9%), and 2008 (30.7%). Rejection was the primary cause leading to readmission in 2007 (40%). Other causes included fluid retention, pericardial effusion, anemia, and systemic diseases. Conclusion: To reduce unplanned readmissions and to promote quality of life and long-term survival, health professionals must meticulously monitor the adverse effects of treatments including immunosuppression agents and concomitantly used medications. [Copyright &y& Elsevier]

Abstract: Introduction: Heart transplantation has become the best available therapy for patients with refractory end-stage heart failure. Cyclosporine (CsA) and mycophenolate mofetil (MMF) are the 2 FDA-approved drugs to prevent posttransplant acute rejection episodes. The purpose of this study was to evaluate the result of heart transplantation treated with CsA and everolimus (EVL), compared with that of patients treated with CsA and MMF. Materials and Methods: From 2000 to 2009 heart transplantation was performed in 239 patients among whom we enrolled 93 patients with a serum creatinine values ≤2.8 mg/dL after informed written consents. The 2 arms were a CE group, who received EVL (n = 46) CsA, and steroid (n = 46), and a CM group who received MMF, CsA, and steroid (n = 47). Results: There was no operative mortality in either groups. The 1- and 5-year survivals of the CE group were 97.67 ± 2.22% and 80.23 ± 6.87%, versus the CM group, 97.72 ± 2.17% and 79.38 ± 7.62%, respectively. There was significant difference between the 2 groups. Conclusion: Survival after heart transplantation under EVL or MMF plus CsA and steroid was good. The survival of patients under the regimen of EVL, CsA and, steroid was not inferior to that of subjects prescribed MMF, CsA and steroid up to 5 years. [Copyright &y& Elsevier]